Dr. Ankit A. Patel, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 406
Licensed in Texas since 2013, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: University of Texas Medical School at Houston
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TX license P6694 (first issued 2013; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann - Texas Medical Center Houston, TX
- Memorial Hermann Memorial City Hospital Houston, TX
- Memorial Hermann Katy Hospital Katy, TX
- Midland Memorial Hospital Midland, TX
- Columbus Community Hospital Columbus, TX
Medical groups
- Mhs Physicians of Texas (113 clinicians)
- Premier Family Care I Inc (76 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 406
- Services billed
- 786
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 290 | 193 |
| Established patient office or other outpatient visit, 40-54 minutes | 86 | 67 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 67 | 32 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 56 | 55 |
| Established patient office or other outpatient visit, 20-29 minutes | 51 | 48 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 50 | 35 |
| Measurement of brain wave activity (eeg), awake and drowsy | 48 | 44 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 41 | 28 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 38 | 36 |
| New patient office or other outpatient visit, 45-59 minutes | 35 | 35 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Katy, TX | 266 |
| Primidone Other prescribers in Katy, TX | 186 |
| Donepezil Hcl Other prescribers in Katy, TX | 116 |
| Levetiracetam Other prescribers in Katy, TX | 114 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Katy, TX | 108 |
| Pregabalin Other prescribers in Katy, TX | 94 |
| Memantine Hcl Other prescribers in Katy, TX | 83 |
| Rasagiline Mesylate | 69 |
| Duloxetine Hcl Other prescribers in Katy, TX | 65 |
| Tizanidine Hcl Other prescribers in Katy, TX | 59 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 154 payments worth $3,026 in total to this clinician.
| AbbVie Inc. | $345 |
|---|---|
| UCB, Inc. | $256 |
| Sk Life Science, Inc. | $233 |
| Novartis Pharmaceuticals Corporation | $215 |
| Argenx US, Inc. | $178 |
| Pfizer Inc. | $165 |
| Lilly USA, LLC | $153 |
| EMD Serono, Inc. | $143 |
| Food and Beverage | $2,970 |
|---|---|
| Education | $55.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Argenx US, Inc. Feb 11, 2025 | Education in-kind | $55.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $52,624 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate SAGE-324 in Participants With Essential Tremors
Sage Therapeutics, LLC - Alzheimer's Disease Master Pre Screener
Genentech, Inc. - ACP-204 in Adults With Alzheimer's Disease Psychosis
Acadia Pharmaceuticals Inc · Recruiting · NCT06159673 - Study name not reported
Novo Nordisk As - A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
Sage Therapeutics, LLC - A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06126224
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.